shire zet er een nieuwe man op.
TIDMSHP
Shire Appoints Andreas Busch, Ph D as Head of Research and Development
and Chief Scientific Officer
Howard Mayer, MD to become Chief Medical Officer
Cambridge, MA - December 1, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG),
the global biotech leader in rare diseases, today announced that Andreas
(Andy) Busch, Ph D, will join Shire as Executive Vice President, Head of
Research and Development and Chief Scientific Officer, and will become a
member of the Company's Executive Committee beginning in January. Howard
Mayer, MD, currently serving as the Company's Head of Research and
Development (ad interim), has been appointed Chief Medical Officer, also
effective in January 2018.
"Andy is an outstanding scientist with extensive experience leading
research and development functions, and an established track record of
building broad portfolios that encompass both biologics and small
molecules," said Flemming Ornskov, MD, MPH, Chief Executive Officer,
Shire. "We look forward to Andy enabling us to further accelerate our
ability to discover novel treatments for our innovative rare disease
pipeline."
Dr. Busch is currently Head of Drug Discovery and a member of the
Executive Committee for the Pharmaceuticals division of Bayer, where he
leads a team of approximately 3,300 researchers. During his 13 years at
Bayer, he has held roles of increasing responsibility within the company,
including Senior Vice President, Head Discovery Europe at Bayer
HealthCare and Executive Vice President, Global Head Drug Discovery. Dr.
Busch was responsible for the Schering drug discovery integration, the
overall R&D strategy and enforced the improvement of Bayer's research
productivity. Prior to joining Bayer, Dr. Busch was Global Head of
Cardiovascular Research at Hoechst and Sanofi-Aventis. Prior to that, he
led independent research groups as a Heisenberg Fellow at the University
of Tübingen and the Max-Planck-Institute for experimental Medicine
in Göttingen.
Dr. Busch is a member of several Supervisory and Scientific Boards,
including the German Cancer Research Center, the University of
Tübingen, the Max-Delbrück-Center and the Max-Planck-Institute
of Molecular Genetics. He also holds the title of Extraordinary
Professor of Pharmacology at the Johann Wolfgang Goethe-University in
Frankfurt, Germany. Dr. Busch received his license to practice Pharmacy
and Ph D in Pharmacology from the Johann Wolfgang Goethe-University
Frankfurt. He is the author of some 400 publications and abstracts, and
received the prestigious Sir Bernard Katz and Franz Volhard Awards for
his work on renal and cardiac ion channels and transporters.
"I am excited by the opportunity to lead the research and development
function for Shire, which has developed and brought to market numerous
high-impact medicines targeting underserved patient populations," said
Dr. Busch. "This is a unique time to join Shire, as it has built an
industry-leading pipeline of rare disease programs in recent years and
has a sharp focus on serial innovation in areas of significant patient
need. I believe there is tremendous opportunity to accelerate this
effort and look forward to leading this talented R&D team."
Howard Mayer, MD, is currently Senior Vice President and Head of R&D (ad
interim) at Shire. Previously, he was Senior Vice President and Head of
Global Clinical Development at the Company. Dr. Mayer joined Shire in
2012 and has been responsible for global clinical development across
immunology, hereditary angioedema, hematology, lysosomal storage
disorders, gastrointestinal / internal medicine / endocrine, ophthalmics,
a growing franchise in oncology, and neuroscience. Prior to joining
Shire, he served as Chief Medical Officer at EMD Serono, a division of
Merck KGaA.